FRIDAY, Oct. 27 (HealthDay News) -- A new drug to help people lose weight, rimonabant (brand named Acomplia), also helps people with type 2 diabetes shed pounds while improving their blood sugar levels, researchers say.

Rimonabant is being tested and is approved in Europe. However, it has not yet been approved for use in the United States. This finding suggests that rimonabant could be used as a new approach for treating diabetes where other drugs have failed.

"This is an interesting new class of drugs that probably offers something new and different to people with diabetes," said Dr. Larry Deeb, president of medicine and science at the American Diabetes Association. He was not involved in the research.

The study was funded by Sanofi-Aventis, the maker of rimonabant, and is published in the Oct. 27 online issue of The Lancet.

In the study, Andre Scheen, from the University of Liege, Belgium, and colleagues looked at the effects of rimonabant in over 1,000 patients with poorly controlled type 2 diabetes. All the patients were obese or overweight and had failed treatment with other drugs.

The patients were given a low-calorie diet plan and advised to be more physically active. They were also given rimonabant at a dose of either 5 milligrams or 20 milligrams per day, or a placebo.

After a year, Scheen's team found that patients taking rimonabant lost significantly more weight than those taking the placebo. Patients on placebo lost an average of 1.4 kilograms, compared with 2.3 kilograms for those given 5 milligrams per day and 5.3 kilograms in patients taking 20 milligrams per day. (For conversion, one kilogram is equal to just over 2 pounds.)

In addition, patients taking rimonabant had greater improvement in waist size, blood sugar control, cholesterol, and better appetite control, compared with patients receiving placebo, the researchers report.

"These findings support the use of 20 mg per day of rimonabant, in addition to diet and exercise, as a new approach to reduce body weight and improve blood glucose control as well as several other cardiovascular risk factors in overweight or obese patients with type 2 diabetes that was inadequately controlled by standard treatment," the researchers concluded.